Teva Pharmaceutical Industries Ltd. $TEVA Stock Sold by Phoenix Financial Ltd.

Phoenix Financial Ltd. decreased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 0.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,625,947 shares of the company’s stock after selling 307,420 shares during the quarter. Teva Pharmaceutical Industries accounts for approximately 11.3% of Phoenix Financial Ltd.’s holdings, making the stock its biggest position. Phoenix Financial Ltd. owned approximately 3.66% of Teva Pharmaceutical Industries worth $1,688,139,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. lifted its stake in Teva Pharmaceutical Industries by 1.3% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 39,422,212 shares of the company’s stock worth $1,561,120,000 after acquiring an additional 500,000 shares in the last quarter. Aberdeen Group plc boosted its position in Teva Pharmaceutical Industries by 28.1% during the 3rd quarter. Aberdeen Group plc now owns 103,897 shares of the company’s stock worth $4,114,000 after acquiring an additional 22,814 shares during the period. EagleClaw Capital Managment LLC acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth about $206,000. Russell Investments Group Ltd. boosted its position in Teva Pharmaceutical Industries by 6.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 453,785 shares of the company’s stock worth $17,969,000 after acquiring an additional 26,341 shares during the period. Finally, Ritholtz Wealth Management grew its stake in Teva Pharmaceutical Industries by 7.9% during the 3rd quarter. Ritholtz Wealth Management now owns 22,103 shares of the company’s stock valued at $875,000 after acquiring an additional 1,613 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In other news, insider Mark Sabag sold 46,000 shares of the company’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the completion of the sale, the insider owned 80,760 shares in the company, valued at approximately $3,386,266.80. This represents a 36.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Roberto Mignone sold 367,600 shares of the stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 715,945 shares of company stock valued at $29,061,351. Insiders own 0.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on TEVA shares. UBS Group upped their target price on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a report on Friday, September 4th. HC Wainwright started coverage on shares of Teva Pharmaceutical Industries in a report on Monday, November 2nd. They set a “buy” rating and a $52.00 price target for the company. Leerink Partners boosted their price objective on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, November 4th. Finally, Piper Sandler increased their target price on shares of Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an “overweight” rating in a research report on Thursday. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.15.

Teva Pharmaceutical Industries Stock Up 2.0%

Shares of Teva Pharmaceutical Industries stock traded up $0.87 during trading on Friday, hitting $44.52. 7,562,490 shares of the stock traded hands, compared to its average volume of 6,968,955. The stock has a market cap of $51.88 billion, a P/E ratio of 103.53, a PEG ratio of 4.09 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.74 and a current ratio of 0.95. Teva Pharmaceutical Industries Ltd. has a twelve month low of $24.01 and a twelve month high of $44.57. The company has a fifty day moving average price of $40.16 and a two-hundred day moving average price of $35.07.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. The firm had revenue of $4.39 billion for the quarter, compared to the consensus estimate of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The firm’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.78 earnings per share. Equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current fiscal year.

Teva Pharmaceutical Industries News Roundup

Here’s some of the latest news about TEVA:

• Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and maintained an Overweight rating, pointing to potential upside. HC Wainwright also issued a positive forecast for Teva’s FY2026 earnings, though the report provided no further details. Piper Sandler analyst rating HC Wainwright forecast
• Positive Sentiment: At its R&D Day, Teva outlined a target of $6–7 billion in innovative-medicines revenue by 2030 and highlighted potential first-in-class pipeline treatments, including for Tourette syndrome, celiac disease and intestinal scarring. These are longer-term opportunities, not guaranteed results. Teva R&D Day announcement
• Negative Sentiment: CEO Richard Francis sold 250,000 shares for about $10.56 million, reducing his direct ownership by 21.23%. EVP Richard Daniell also sold shares in two reported transactions—20,003 shares on Nov. 11 and 25,000 on Nov. 9—cutting his reported stake. Insider selling can weigh on sentiment, although it does not by itself establish the executives’ view of Teva’s prospects. CEO SEC filing EVP SEC filing

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.